Hsp90 in Cancer: Beyond the Usual Suspects

Hsp90 in Cancer: Beyond the Usual Suspects

1st Edition - February 22, 2016

Write a review

  • Editors: Jennifer Isaacs, Luke Whitesell
  • Hardcover ISBN: 9780128022900
  • eBook ISBN: 9780128024836

Purchase options

Purchase options
Available
DRM-free (EPub, Mobi, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Hsp90 in Cancer: Beyond the Usual Suspects, the latest volume in the Advances in Cancer Research series, focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins and discusses some of the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression.

Key Features

  • Focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins
  • Highlights the rapidly evolving understanding of the fundamental roles of Hsp90 in cancer biology
  • Discusses the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression

Readership

The information in this volume will be of interest to a broad range of basic and translational scientists, not only in the relatively narrow field of protein folding/biochemistry, but in other areas of cancer biology and clinical oncology.

Table of Contents

  • 1. Unusual Suspects in the Twilight Zone between the Hsp90 Interactome and Carcinogenesis
    Evangelia Vartholomaiou, Pablo C. Echeverría and Didier Picard
    2. Impact of Post-translational Modifications on the Anticancer Activity of Hsp90 Inhibitors
    Mark R. Woodford, Diana Dunn, Jonelle B. Miller,Sami Jamal, Len Neckers and Mehdi Mollapour
    3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects
    Gaurav Garg, Anuj Khandelwal and Brian S. J. Blagg
    4. HSP90 in Cancer:  Transcriptional Roles in the Nucleus
    S. K. Calderwood and L. Neckers
    5. Hsp90 as a ‘Chaperone’ of the Epigenome: Insights and Opportunities for Cancer Therapy
    Jennifer S. Isaacs
    6. Emerging Roles of Extracellular Hsp90 in Cancer
    Daniel Senh Wong and Daniel G. Jay
    7. GRP94/gp96 in Cancer: Biology, Structure, Immunology and Drug Development
    Bill X Wu, Feng Hong, Yongliang Zhang, Ephraim Ansa-Addo and Zihai Li
    8. HSP90 and Immune Modulation in Cancer
    Michael W. Graner
    9. Hsp90: A Global Regulator of the Genotype-To-Phenotype Map in Cancers
    Daniel Jarosz

Product details

  • No. of pages: 288
  • Language: English
  • Copyright: © Academic Press 2016
  • Published: February 22, 2016
  • Imprint: Academic Press
  • Hardcover ISBN: 9780128022900
  • eBook ISBN: 9780128024836

About the Serial Volume Editors

Jennifer Isaacs

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA

Luke Whitesell

Luke Whitesell is a pediatric oncologist and senior research scientist at the Whitehead Institute. His clinical interests lie in the treatment of children with recurrent, refractory solid tumors. His laboratory efforts focus on the discovery and pre-clinical development of new anticancer drugs that target heat-shock proteins and the cellular heat-shock response. These ancient adaptive mechanisms act genome-wide to restore the normal protein folding environment within cells and enhance the survival of organisms under stress. In contrast to such well-recognized beneficial effects, however, they also enable cells to accommodate the drastic imbalances in signaling and profound alterations in DNA, protein and energy metabolism that occur in cancers. In essence, the malignant lifestyle confers a profound dependence on these “non-oncogenes”, strongly supporting the feasibility of targeting them to more effectively treat cancers. Building on these basic insights and the surprising ways in which HSP90 supports the evolution of new abilities in model organisms, a major goal of his current work is to test the idea that inhibiting HSP90 function can delay or prevent the evolution of a very undesirable trait in cancers, namely the acquisition of high level resistance to current chemotherapies.

Luke pursued graduate work in pharmacology at Cambridge University prior to completing medical training at Johns Hopkins University and residency at Boston Children’s Hospital. After fellowship training at the National Cancer Institute he joined the University of Arizona where he was Professor of Pediatric Oncology in the College of Medicine prior to taking his current position at the Whitehead Institute in Cambridge, MA.

Affiliations and Expertise

Whitehead Institute for Biomedical Research, Cambridge, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Hsp90 in Cancer: Beyond the Usual Suspects"